Put Options

8 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$134.21 - $153.93 $429,472 - $492,576
-3,200 Reduced 23.7%
10,300 $1.38 Million
Q2 2022

Aug 15, 2022

SELL
$137.62 - $174.96 $233,954 - $297,432
-1,700 Reduced 11.18%
13,500 $2.07 Million
Q1 2022

May 16, 2022

BUY
$131.98 - $163.75 $1.19 Million - $1.47 Million
9,000 Added 145.16%
15,200 $2.46 Million
Q4 2021

Feb 14, 2022

SELL
$107.43 - $135.93 $773,496 - $978,696
-7,200 Reduced 53.73%
6,200 $839,000
Q3 2021

Nov 15, 2021

BUY
$106.4 - $120.78 $808,640 - $917,928
7,600 Added 131.03%
13,400 $1.45 Million
Q2 2021

Aug 16, 2021

SELL
$105.21 - $117.21 $347,193 - $386,793
-3,300 Reduced 36.26%
5,800 $653,000
Q1 2021

May 17, 2021

SELL
$102.3 - $112.62 $2.02 Million - $2.22 Million
-19,700 Reduced 68.4%
9,100 $985,000
Q4 2020

Feb 16, 2021

BUY
$80.49 - $108.67 $2.32 Million - $3.13 Million
28,800 New
28,800 $3.09 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $317B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Point72 Hong Kong LTD Portfolio

Follow Point72 Hong Kong LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

News

Stay updated on Point72 Hong Kong LTD with notifications on news.